RPRX:NSD-Royalty Pharma Plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 40.23

Change

+0.35 (+0.88)%

Market Cap

USD 27.26B

Volume

1.23M

Avg Analyst Target

USD 52.56 (+30.64%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


RPRX Stock Forecast & Price:
Based on the Royalty Pharma Plc stock forecasts from 7 analysts, the average analyst target price for Royalty Pharma Plc is USD 52.56 over the next 12 months. Royalty Pharma Plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Royalty Pharma Plc is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Royalty Pharma Plc’s stock price was USD 40.23. Royalty Pharma Plc’s stock price has changed by -1.93% over the past week, -6.55% over the past month and +8.29% over the last year.

About Royalty Pharma Plc (RPRX:NSD)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+8.91 (+1.30%)

USD74.83B 13.56 10.63
VRTX Vertex Pharmaceuticals Inc

+7.96 (+2.88%)

USD72.69B 23.18 15.56
MRNA Moderna Inc

+2.54 (+2.12%)

USD48.37B 3.83 2.59
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.65 (+2.08%)

USD31.55B 2.99 1.31
SGEN Seagen Inc

+0.08 (+0.06%)

USD24.95B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

+5.22 (+2.64%)

USD23.69B N/A -31.40
GMAB Genmab AS

+0.30 (+0.95%)

USD21.80B 40.29 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx NV ADR

+7.26 (+2.11%)

USD20.07B N/A -18.86

ETFs Containing RPRX

Symbol Name Weight Mer Price(Change) Market Cap
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.39 %

-0.12 (-0.07%)

USD0.40B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.97 %

+0.06 (+0.70%)

USD0.01B
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.11 (+0.28%)

USD0.22B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.95% 88% B+ 86% B
Dividend Return 1.43% 29% F 43% F
Total Return 2.38% 88% B+ 90% A-
Trailing 12 Months  
Capital Gain 9.86% 92% A- 93% A
Dividend Return 2.02% 29% F 43% F
Total Return 11.88% 92% A- 93% A
Trailing 5 Years  
Capital Gain 50,187.50% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50,187.50% 100% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 1.79% 65% D 57% F
Dividend Return 0.56% 21% F 16% F
Total Return 2.35% 65% D 54% F
Risk Return Profile  
Volatility (Standard Deviation) 17.98% 96% A 74% C
Risk Adjusted Return 13.05% 69% D+ 51% F
Market Capitalization 27.26B 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.16 19% F 23% F
Price/Book Ratio 2.94 33% F 27% F
Price / Cash Flow Ratio 13.51 4% F 17% F
EV/EBITDA 19.50 2% F 11% F
Management Effectiveness  
Return on Equity 8.60% 94% A 68% D+
Return on Invested Capital 12.17% 88% B+ 80% B-
Return on Assets 3.85% 96% A 80% B-
Debt to Equity Ratio 122.84% 13% F 18% F
Technical Ratios  
Dividend Yield 1.85% 44% F 31% F
Short Ratio 6.09 34% F 24% F
Short Percent 3.22% 52% F 42% F
Beta 0.30 86% B 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.